Technology
Health
Biotechnology

Correvio Pharma

$3.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.82%) Today
+$0.03 (0.82%) Today

Why Robinhood?

You can buy or sell CORV and other stocks, options, ETFs, and crypto commission-free!

About

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. Read More The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients, and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Employees
138
Headquarters
Vancouver, British Columbia
Founded
1986
Market Cap
132.98M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
198.72K
High Today
$3.70
Low Today
$3.62
Open Price
$3.69
Volume
6.12K
52 Week High
$5.24
52 Week Low
$1.68

Collections

Technology
Health
Biotechnology
Pharmaceutical
Medical
Healthcare
Canada
North America

News

Simply Wall StMar 14

Are Insiders Selling Correvio Pharma Corp. (TSE:CORV) Stock?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we’ll take a look at whether insiders have been buying or selling shares in Correvio Pharma Corp. (TSE:CORV). What Is Insider Buying? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. However, such i...

22
Seeking AlphaMar 13

Correvio Pharma Corp. (CORV) CEO Dr. Bill Hunter on Q4 2018 Results - Earnings Call Transcript

Correvio Pharma Corp. (NASDAQ:CORV) Q4 2018 Results Earnings Conference Call March 13, 2019 8:00 AM ET Company Participants Justin Renz - Chief Financial Officer Dr. Bill Hunter - President and CEO Dr. Mark Corrigan - Incoming CEO David Dean - Chief Business Development Officer Conference Call Participants Dewey Steadman - Canaccord Swayampakula Ramakanth - H.C. Wainwright PJ Solit - Potomac Capital Operator Good afternoon, ladies and gentlemen, and welcome to Correvio's Fourth Quarter and Year-E...

0
PR NewswireMar 7

Correvio to Present at Upcoming Investor Conferences

NASDAQ: CORV TSX: CORV VANCOUVER, March 7, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Correvio management will present at the following upcoming investor conferences: The Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 a.m. EST at the Boston Marriott Copley Place. The webcast of the Cowen presentation can be accessed through the following...

14

Earnings

-$0.37
-$0.27
-$0.17
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.21 per share
Actual
-$0.18 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.